Cubist Systematic Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cubist Systematic Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,300	Closed	-$162K	–	2996
2024 Q3	$162K	Buy	+2,300	New	+$192K	﹤0.01%	2620
2024 Q2	–	Sell	-3,900	Closed	-$341K	–	3028
2024 Q1	$341K	Sell	3,900 -100	-3%	-$8.95K	﹤0.01%	2826
2023 Q4	$386K	Sell	4,000 -7,500	-65%	-$664K	﹤0.01%	2663
2023 Q3	$1.02M	Buy	+11,500	New	+$1.02M	0.01%	1875
2023 Q2	–	Sell	-3,900	Closed	-$379K	–	3539
2023 Q1	$379K	Buy	+3,900	New	+$404K	﹤0.01%	2835

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Cubist Systematic Strategies's BMRN Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 165,408 shares — an estimated $9.74M sold.

Cubist Systematic Strategies first reported a position in BMRN in Q2 2014 and held it in 40 quarters. The position peaked at $17.3M in Q2 2023. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

Cubist Systematic Strategies reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 165,408 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $9.74M.
Cubist Systematic Strategies first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 40 quarters.
Cubist Systematic Strategies's BioMarin Pharmaceuticals position peaked at $17.3M in Q2 2023.
582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.